GeoVax Revenue and Competitors

Claim your profile

Atlanta, GA USA

Location

$28M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • GeoVax's estimated annual revenue is currently $1.6M per year.(i)
  • GeoVax's estimated revenue per employee is $77,500
  • GeoVax's total funding is $28M.

Employee Data

  • GeoVax has 21 Employees.(i)
  • GeoVax grew their employee count by -12% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$2M13-13%N/AN/A
#2
$14.7M9514%$0.07BN/A
#3
$3.3M516%N/AN/A
#4
$9.6M62-11%N/AN/A
#5
$287.3M1464-20%$101.3MN/A
#6
$19.1M12348%$20.3MN/A
#7
$37.8M19520%$14.2MN/A
#8
$3.8M6011%N/AN/A
#9
$16.1M12720%N/AN/A
#10
$0.3M4-20%$2.8MN/A

GeoVax is a Biotechnology company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus - AIDS) and other infectious agents. Our goals include: developing AIDS vaccines for global markets, manufacturing and testing these vaccines under GMP/GLP conditions (FDA guidelines), conducting phase I/II and III human trials for vaccine safety and effectiveness and obtaining regulatory approval of these vaccines in the USA and specified international markets. Outstanding preclinical results: GeoVax DNA/MVA vaccine protected 96% of non-human primates for over 3½ yrs. To our knowledge, this level of protection has not been achieved by other candidate vaccines.

keywords:Biotechnology

$28M

Total Funding

21

Number of Employees

$1.6M

Revenue (est)

-12%

Employee Growth %

N/A

Valuation

N/A

Accelerator

GeoVax News

2022-04-20 - USPTO Issues Malaria Vaccine Patent to GeoVax

GeoVax Labs, a biotechnology company focused on the development of vaccines and immunotherapies, announced on April 26, 2022 that the US...

2022-04-20 - USPTO Issues Malaria Vaccine Patent to GeoVax

GeoVax Labs, a biotechnology company focused on the development of vaccines and immunotherapies, announced on April 26, 2022 that the US...

2022-04-17 - GeoVax Announces Issuance of Malaria Vaccine Patent

GeoVax's Unique Multi-Antigenic Vaccine Approach Designed to Provide Stronger, Broader Protection Against Malaria Atlanta, GA, April 26,...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$2.2M2210%N/A
#2
$4.9M28-15%N/A
#3
$4.3M3148%N/A
#4
$15M327%N/A
#5
$4.3M320%N/A